Please login to the form below

Not currently logged in
Email:
Password:

Robocath appoints CEO

Pascal Guy promoted at medical robotics start-up

Robocath Pascal GuyRouen, France-based Robocath, a medical robotics start-up specialising in endovascular procedures, has formerly appointed Pascal Guy as its new chief executive officer.

Guy first joined Robocath in 2015 as a consultant, and has since gradually assumed the role of chief executive. He will now oversee the clinical development and rollout of the R-One robot, as well as work to consolidate the firm's intellectual property and assets.

He brings over 20 years of medtech experience to the start-up, most recently at US firm Stryker Neurovascular, where he served as international vice president.

Prior to this, Guy was global vice president of sales and marketing for Europe and Japan with the Sorin Group, and worked at Boston Scientific from 1996 to 2007.

Philippe Bencteux, founder and president of Robocath, said: “We are delighted to welcome Pascal Guy in this strategic management position, especially since Robocath is currently at a pivotal moment in its development.

"Thanks to his wealth of experience working with vascular medical devices in some of the leading companies, he will bring to Robocath his strategic management skills, his understanding of the needs of the sector and his up-to-date knowledge of the market.”

4th January 2017

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics